Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.62 EUR
−201.46 M EUR
291.73 K EUR
73.55 M
About Viridian Therapeutics, Inc.
Sector
Industry
CEO
Stephen Frank Mahoney
Website
Headquarters
Waltham
Founded
2006
ISIN
US92790C1045
FIGI
BBG01JLD6M28
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1S1 is 15.97 EUR — it has decreased by −3.05% in the past 24 hours. Watch Viridian Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange Viridian Therapeutics, Inc. stocks are traded under the ticker 1S1.
1S1 stock has risen by 3.18% compared to the previous week, the month change is a 1.27% rise, over the last year Viridian Therapeutics, Inc. has showed a −12.76% decrease.
We've gathered analysts' opinions on Viridian Therapeutics, Inc. future price: according to them, 1S1 price has a max estimate of 52.42 EUR and a min estimate of 22.34 EUR. Watch 1S1 chart and read a more detailed Viridian Therapeutics, Inc. stock forecast: see what analysts think of Viridian Therapeutics, Inc. and suggest that you do with its stocks.
1S1 stock is 3.37% volatile and has beta coefficient of 1.08. Track Viridian Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Viridian Therapeutics, Inc. there?
Today Viridian Therapeutics, Inc. has the market capitalization of 1.31 B, it has decreased by −1.56% over the last week.
Yes, you can track Viridian Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viridian Therapeutics, Inc. is going to release the next earnings report on Nov 18, 2025. Keep track of upcoming events with our Earnings Calendar.
1S1 earnings for the last quarter are −0.85 EUR per share, whereas the estimation was −0.86 EUR resulting in a 0.92% surprise. The estimated earnings for the next quarter are −0.81 EUR per share. See more details about Viridian Therapeutics, Inc. earnings.
Viridian Therapeutics, Inc. revenue for the last quarter amounts to 63.67 K EUR, despite the estimated figure of 43.22 K EUR. In the next quarter, revenue is expected to reach 31.79 K EUR.
1S1 net income for the last quarter is −85.51 M EUR, while the quarter before that showed −80.34 M EUR of net income which accounts for −6.45% change. Track more Viridian Therapeutics, Inc. financial stats to get the full picture.
No, 1S1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 15, 2025, the company has 143 employees. See our rating of the largest employees — is Viridian Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Viridian Therapeutics, Inc. EBITDA is −314.52 M EUR, and current EBITDA margin is −98.61 K%. See more stats in Viridian Therapeutics, Inc. financial statements.
Like other stocks, 1S1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viridian Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Viridian Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Viridian Therapeutics, Inc. stock shows the strong buy signal. See more of Viridian Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.